Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
about
Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users.Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneTamper-resistant opioid formulations in the treatment of acute pain.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Drug Formulation Advances in Extended-Release Medications for Pain Control.Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.In response to Gudin et al. - Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.Response to Crudele et al. Commentary on Gudin et al. "Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties".Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users.Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration.Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.
P2860
Q30240248-E2FF84B2-C2F9-4732-BF25-1F42A890252CQ33685208-75A37467-EE44-4D4F-9A51-AB7AC9DDA821Q34808676-0B8B723C-58B9-4B01-B35F-0C71C69EF6EDQ36972164-18508FB0-AF21-42AA-9FFA-5E5FFF271D56Q38187910-81765AB7-6634-48EA-93D1-CA4C784C2DA3Q38683620-3D97F9C9-E0DE-4593-B632-4E71CA40A5F8Q38809652-07AD7B99-D01B-4D96-BD94-253A2CD48642Q40800503-9B59C974-CDFE-4816-A58A-C982B61EFA50Q41871913-AD943425-B532-4621-9188-93489295B817Q42267511-BDE21C2C-ABE3-4177-9BDA-B9AC8B5E6A2FQ44340245-B73E5343-685F-44A0-8C4A-791EA287BF4AQ44349641-050A2055-CC01-4077-A034-5108134F42E5Q55073574-20FD57ED-F6DE-42FB-A0A4-C058A31AC619
P2860
Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Pharmacokinetics, tolerability ...... (®) tablets in healthy adults.
@en
type
label
Pharmacokinetics, tolerability ...... (®) tablets in healthy adults.
@en
prefLabel
Pharmacokinetics, tolerability ...... (®) tablets in healthy adults.
@en
P2093
P2860
P1476
Pharmacokinetics, tolerability ...... (®) tablets in healthy adults.
@en
P2093
Glen Apseloff
Peter J Perrino
Salvatore V Colucci
Stephen C Harris
P2860
P304
P356
10.1007/S40261-013-0085-X
P577
2013-06-01T00:00:00Z